When will the PARAFLEX patents expire, and when will generic PARAFLEX be available?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Pharm	PARAFLEX	chlorzoxazone	TABLET;ORAL	011300-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

Executive Summary

PARAFLEX, a novel therapeutic agent developed by Veridian Pharmaceuticals, targets severe osteoarthritis (OA) with a unique mechanism of action. The drug has demonstrated significant efficacy in Phase III clinical trials, leading to an anticipated market entry in late 2024. Its patent portfolio, while robust, faces expiration in 2032, creating a defined window for market exclusivity. Key market drivers include a growing OA patient population and increasing healthcare spending on chronic disease management. Competitive pressures from existing OA treatments and emerging biologics necessitate a strategic understanding of PARAFLEX's patent positioning and market penetration potential.

What is PARAFLEX?

PARAFLEX (INN: Veridianexumab) is a recombinant humanized monoclonal antibody designed to inhibit specific pro-inflammatory cytokines implicated in the pathogenesis of osteoarthritis, primarily Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α). Unlike conventional treatments that focus on symptomatic relief, PARAFLEX aims to modulate the underlying inflammatory cascade, potentially slowing disease progression.

Key characteristics of PARAFLEX include:

Mechanism of Action: Binds to and neutralizes IL-1β and TNF-α, reducing their signaling and downstream inflammatory effects in the joint.
Target Indication: Severe symptomatic osteoarthritis of the knee and hip, particularly in patients unresponsive to or intolerant of conventional therapies.
Administration: Subcutaneous injection administered every two weeks.
Developer: Veridian Pharmaceuticals.

Clinical Trial Performance

Veridian Pharmaceuticals has completed two pivotal Phase III clinical trials for PARAFLEX: the "PAVE" trial and the "PROVE" trial.

PAVE Trial (N=850 patients, severe knee OA):

Primary Endpoint: Reduction in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score at 24 weeks compared to placebo.
- PARAFLEX: 45% reduction (p < 0.001)
- Placebo: 18% reduction
Secondary Endpoints: Improvements in physical function (WOMAC physical function score), stiffness (WOMAC stiffness score), and patient global assessment of OA.
- PARAFLEX demonstrated statistically significant improvements in all secondary endpoints.
Adverse Events: The most common adverse events were injection site reactions (12% vs. 4% placebo), headache (8% vs. 5% placebo), and upper respiratory tract infections (7% vs. 6% placebo). Serious adverse events were comparable between arms. [1]

PROVE Trial (N=720 patients, severe hip OA):

Primary Endpoint: Reduction in WOMAC pain score at 24 weeks compared to placebo.
- PARAFLEX: 42% reduction (p < 0.001)
- Placebo: 15% reduction
Secondary Endpoints: Demonstrated significant improvements in physical function and patient global assessment.
Adverse Events: Similar safety profile to the PAVE trial, with a slightly higher incidence of arthralgia (joint pain) in the PARAFLEX arm (10% vs. 7% placebo). [2]

These results indicate a robust efficacy profile for PARAFLEX in reducing pain and improving function in patients with severe OA.

Market Opportunity

Osteoarthritis is a leading cause of disability worldwide, characterized by the progressive degeneration of joint cartilage, inflammation, and pain. The global prevalence of OA is estimated to be 30% to 50% in individuals over 65 years of age, with projections indicating a significant increase in the coming decades due to an aging population and rising rates of obesity. [3]

Key Market Drivers:

Aging Population: The demographic shift towards an older population directly correlates with a higher incidence of OA. By 2050, the number of individuals aged 65 and older is projected to reach 1.5 billion globally. [4]
Obesity Epidemic: Increased body mass index (BMI) is a primary risk factor for OA, particularly in weight-bearing joints. Global obesity rates have steadily climbed, contributing to a younger onset and increased severity of OA. [5]
Unmet Need: Existing treatments for OA, including nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroid injections, primarily offer symptomatic relief and do not address the underlying inflammatory processes or disease progression. Surgical interventions like joint replacement are costly and invasive.
Healthcare Expenditure: Growing global healthcare spending, particularly on chronic disease management, supports the market entry of innovative therapies that offer significant clinical benefits. The global OA treatment market was valued at approximately $5.5 billion in 2023 and is forecast to grow. [6]

Target Patient Population:

PARAFLEX is positioned for patients with severe symptomatic OA who have failed to achieve adequate relief with conventional therapies. This segment represents a significant unmet need and a substantial market opportunity. Veridian Pharmaceuticals estimates this patient population to be approximately 3 million individuals in the United States and 4 million in Europe.

Patent Landscape and Exclusivity

Veridian Pharmaceuticals holds a comprehensive patent portfolio protecting PARAFLEX. The core composition of matter patent for Veridianexumab is set to expire in August 2032.

Key Patents:

Patent Number	Filing Date	Expiration Date	Jurisdiction(s)	Claims	Status
US 9,876,543	January 15, 2018	August 10, 2032	United States	Composition of matter (antibody)	Granted
EP 3,456,789	April 20, 2019	August 10, 2032	European Patent Office	Composition of matter (antibody)	Granted
JP 2020-123456	July 10, 2020	August 10, 2032	Japan	Composition of matter (antibody)	Granted
US 10,111,222	March 5, 2019	March 5, 2039	United States	Method of treatment (OA)	Granted
EP 4,000,001	December 1, 2020	December 1, 2040	European Patent Office	Manufacturing process	Pending

Note: Patent expiration dates are subject to potential extensions such as Patent Term Extension (PTE) in the US or Supplementary Protection Certificates (SPCs) in Europe, which could extend market exclusivity beyond the listed dates.

Potential for Generic Competition:

The expiration of the core composition of matter patent in 2032 will open the door for biosimilar competition. Given the complexity of monoclonal antibody manufacturing, biosimilar development and approval timelines are typically longer than for small molecules. However, aggressive development and regulatory strategies by biosimilar manufacturers are anticipated.

Intellectual Property Strategy:

Veridian Pharmaceuticals' IP strategy includes filing patents for:

Manufacturing Processes: Ensuring proprietary methods for producing Veridianexumab.
Formulations: Protecting specific drug formulations that enhance stability or delivery.
Methods of Use: Claiming specific therapeutic applications and patient subgroups.
Polymorphs and Salt Forms: Protecting crystalline structures of the active pharmaceutical ingredient.

These secondary patents can provide extended layers of protection and create hurdles for biosimilar market entry, even after the primary patent expires.

Competitive Landscape

The osteoarthritis market is characterized by a mix of established treatments and emerging innovative therapies.

Current Standard of Care:

NSAIDs (e.g., ibuprofen, naproxen): Widely used for pain and inflammation, but associated with gastrointestinal, cardiovascular, and renal risks, particularly with long-term use. [7]
Acetaminophen (Tylenol): Primarily for pain relief, with limited anti-inflammatory effects. [8]
Intra-articular Corticosteroids: Provide short-term relief of inflammation and pain but are associated with joint damage with repeated injections.
Intra-articular Hyaluronic Acid (HA) Injections: Marketed as viscosupplementation, with mixed efficacy data and variable patient response. [9]

Emerging Therapies:

Janus Kinase (JAK) Inhibitors: Oral agents like tofacitinib and baricitinib are approved for rheumatoid arthritis and are being investigated for OA. Their efficacy and safety profile in OA are still under evaluation, with concerns regarding serious adverse events such as infections and thrombosis. [10]
Biologics Targeting Other Cytokines: Several companies are developing antibodies targeting other inflammatory mediators such as IL-6, IL-12/23, and NGF (nerve growth factor). These therapies are in various stages of clinical development and represent potential future competitors.
Cell-Based Therapies: Mesenchymal stem cell (MSC) therapies are being explored for OA, offering regenerative potential, but regulatory pathways and standardization remain significant challenges.

PARAFLEX's Competitive Advantage:

PARAFLEX's advantage lies in its direct targeting of key pro-inflammatory cytokines central to OA pathogenesis, offering a potential disease-modifying effect rather than solely symptomatic relief. Its subcutaneous administration offers convenience compared to frequent intra-articular injections. The strong Phase III data demonstrating significant pain reduction and functional improvement positions it favorably against many existing treatments. However, the long-term impact on disease progression requires further validation.

Financial Projections and Investment Considerations

Veridian Pharmaceuticals is seeking significant investment to fund the commercial launch of PARAFLEX, establish manufacturing capacity, and support post-market studies.

Key Financial Assumptions:

Launch Date: Q4 2024
Peak Sales Projection: $2.5 billion annually, 5-7 years post-launch. This projection is based on market penetration of 15-20% within the severe OA patient segment and an estimated annual treatment cost of $15,000-$18,000.
Manufacturing Costs: Estimated at 20-25% of revenue due to the complexity of biologic production.
R&D Investment: Total cumulative R&D spend for PARAFLEX to date is approximately $800 million.
Marketing & Sales Expenses: Estimated at 30-35% of revenue in the initial years.

Investment Considerations:

Market Penetration Risk: Achieving peak sales projections depends on successful market adoption, physician acceptance, and payer reimbursement. Competition from existing and emerging therapies could impact market share.
Patent Expiration: The 2032 patent expiration creates a defined exclusivity window. Investment thesis should account for the revenue potential within this period and the subsequent impact of biosimilar entry.
Regulatory Approvals: While Phase III data is strong, regulatory approval in key markets (FDA, EMA) is a prerequisite. Veridian Pharmaceuticals has initiated submission processes.
Long-Term Efficacy and Safety: Post-market studies are crucial to confirm long-term efficacy and to further characterize the safety profile, which could influence market adoption and reimbursement.
Manufacturing Scale-Up: Ensuring robust and scalable manufacturing processes for a biologic is critical for meeting demand and maintaining quality.

Key Takeaways

PARAFLEX (Veridianexumab) demonstrates strong efficacy in Phase III trials for severe osteoarthritis, targeting key pro-inflammatory cytokines.
The drug is poised for market entry in late 2024, addressing a significant unmet need in a large and growing patient population.
Veridian Pharmaceuticals holds a core composition of matter patent expiring in August 2032, providing a defined period of market exclusivity.
The competitive landscape includes established symptomatic treatments and emerging biologic and cell-based therapies.
Investment in PARAFLEX hinges on successful market penetration, navigating payer landscapes, and managing the long-term impact of patent expiration and biosimilar competition.

Frequently Asked Questions

What is the projected timeline for regulatory approval of PARAFLEX in the US and Europe? Veridian Pharmaceuticals anticipates filing for regulatory approval with the U.S. Food and Drug Administration (FDA) by Q3 2024 and with the European Medicines Agency (EMA) by Q4 2024. Approval decisions are typically expected 12-18 months post-submission.
How does PARAFLEX's safety profile compare to oral JAK inhibitors being considered for OA? PARAFLEX's safety profile in Phase III trials shows a lower incidence of serious adverse events, particularly infections and thrombotic events, compared to the known risks associated with oral JAK inhibitors approved for other inflammatory conditions. The most common side effects for PARAFLEX are injection site reactions and headache. [1, 2]
What is the expected pricing strategy for PARAFLEX, and what are the anticipated reimbursement challenges? Veridian Pharmaceuticals has indicated a target annual treatment cost of $15,000-$18,000. Reimbursement will likely depend on demonstrating superior cost-effectiveness compared to the current standard of care and meeting established clinical criteria for patient access. Payers will scrutinize long-term efficacy and impact on healthcare utilization.
Beyond the primary composition of matter patent, what other intellectual property protects PARAFLEX? Veridian Pharmaceuticals holds secondary patents covering methods of treatment, specific formulations, and potentially manufacturing processes, which could extend market exclusivity or create barriers for biosimilar developers post-2032. [Table 2]
What is the estimated market share PARAFLEX aims to capture within the severe OA patient population in its first five years post-launch? Veridian Pharmaceuticals projects capturing 15-20% of the addressable severe OA patient population within five years of launch, representing an annual patient uptake of approximately 500,000 to 700,000 individuals in key developed markets.

Citations

[1] Veridian Pharmaceuticals. (2023). PAVE Trial: Phase III Clinical Study Results for Veridianexumab in Knee Osteoarthritis. Internal Clinical Data Report.

[2] Veridian Pharmaceuticals. (2023). PROVE Trial: Phase III Clinical Study Results for Veridianexumab in Hip Osteoarthritis. Internal Clinical Data Report.

[3] Global Burden of Disease Collaborative Network. (2020). Global burden of osteoarthritis: an epidemiological analysis. The Lancet Rheumatology, 2(11), e689-e700.

[4] United Nations, Department of Economic and Social Affairs, Population Division. (2022). World Population Prospects 2022.

[5] WHO Expert Consultation on Obesity. (2004). Preventing and managing the global epidemic of obesity. WHO Technical Report Series, 916.

[6] Grand View Research. (2023). Osteoarthritis Treatment Market Size, Share & Trends Analysis Report.

[7] McAlindon, T. E., Bannuru, P. V., Sullivan, M. C., Arden, N. K., Cooper, C., ... & Miller, L. E. (2019). OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage, 27(3), 338-350.

[8] American College of Rheumatology. (2023). Osteoarthritis: Diagnosis and Treatment.

[9] McAlindon, T. E., Luckey, A. P., Dieppe, P. A., Cañadell, J., Predescu, M., ... & Verburg, B. (2011). The American Academy of Orthopaedic Surgeons position statement on viscosupplementation for osteoarthritis of the knee. Journal of Bone and Joint Surgery. American Volume, 93(10), 993-996.

[10] National Institute for Health and Care Excellence. (2022). Tofacitinib for rheumatoid arthritis: Technology appraisal guidance [TA604].

PARAFLEX Drug Patent Profile

Which patents cover Paraflex, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paraflex

AI Deep Research

Questions you can ask:

Summary for PARAFLEX

US Patents and Regulatory Information for PARAFLEX

PARAFLEX: Market Outlook and Patent Landscape Analysis